Howe & Rusling’s BridgeBio Pharma BBIO Stock Holding History

Howe & Rusling’s Portfolio BBIO Stock Details BBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-140	Closed	-$4K	–	805
2020 Q1	$4K	Buy	+140	New	+$4.34K	﹤0.01%	525

Other funds holding BBIO

KKRC

Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

AIG

American International Group New York $609M AUM 23.67% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return

ACM

Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

Howe & Rusling's BBIO Position: Q2 2020 in Review

Howe & Rusling sold out of BridgeBio Pharma (BBIO) in Q2 2020, closing a stake of 140 shares — an estimated $4K sold.

Howe & Rusling first reported a position in BBIO in Q1 2020 and held it in 1 quarter. The position peaked at $4K in Q1 2020. 116 funds tracked by Wall St. Rank hold BBIO as of Q2 2020.

Howe & Rusling reported no remaining BridgeBio Pharma position as of Q2 2020 after selling out during the quarter.
Howe & Rusling sold 140 BridgeBio Pharma shares in Q2 2020, an estimated $4K.
Howe & Rusling first reported a position in BridgeBio Pharma in Q1 2020 and held it in 1 quarter.
Howe & Rusling's BridgeBio Pharma position peaked at $4K in Q1 2020.
116 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q2 2020.

Based on Howe & Rusling's 13F filing for Q2 2020, filed 15 Jul 2020.